|国家科技期刊平台
首页|期刊导航|中国输血杂志|血小板lncRNA在肺腺癌早期筛查中的生物标志物初步研究

血小板lncRNA在肺腺癌早期筛查中的生物标志物初步研究OACSTPCD

Platelet lncRNA as a biomarker for early screening of lung adenocarcinoma:a preliminary study

中文摘要英文摘要

目的 探究血小板长链非编码RNA(long noncoding RNA,lncRNA)在肺腺癌(lung adenocarcinoma,LUAD)早期筛查中作为生物标志物的诊断价值.方法 对包含LUAD患者和健康对照者血小板RNA数据的GSE183635 和GSE89843数据集做差异分析,将两数据集的差异表达lncRNA(differentially expressed lncRNA,DElncRNA)取交集.通过GEPIA2 分析DElncRNA在LUAD组织与正常对照组织中的表达水平.用实时荧光定量PCR(quantitative real-time PCR,qRT-PCR)检测LINC01088 在51 名健康对照者血小板和54 名LUAD患者血小板中的表达水平,并通过受试者工作(receiver operator characteristic,ROC)曲线评价诊断能力.结果 GSE183635 数据集差异分析得到 8 个DElncR-NAs,GSE89843 数据集差异分析得到1 265 个DElncRNAs,取交集后获得关键DElncRNA LINC01088.GEPIA2 分析显示,LINC01088 在LUAD组织中的表达水平低于正常肺组织(P<0.05).qRT-PCR 验证了血小板LINC01088 在LUAD患者和早期LUAD患者中下调(P均<0.001).血小板LINC01088 对LUAD诊断的曲线下面积(area under the curve,AUC)为0.755,灵敏度为81.1%,特异度为 67.9%;对早期LUAD诊断的AUC为 0.727,灵敏度为 80.0%,特异度为 67.9%;血小板LINC01088 与癌胚抗原(carcinoembryonic antigen,CEA)构成的联合诊断模型对LUAD诊断的AUC为 0.807,灵敏度为89.2%,特异度为 71.4%;对早期LUAD的AUC为 0.770,灵敏度为 86.7%,特异度为 71.4%.血小板LINC01088 与CEA联合诊断模型优于CEA对LUAD及早期LUAD的诊断效能(Z分别=-2.288,-2.34,P均<0.05).结论 LINC01088 在LUAD患者的血小板中下调,血小板LINC01088 可能是LUAD的早期筛查诊断生物标志物.

Objective To explore the diagnostic value of platelet long non-coding RNA(lncRNA)as a biomarker for early screening of lung adenocarcinoma(LUAD).Methods The GSE183635 and GSE89843 datasets,which contained the platelet transcriptome of LUAD and healthy controls,were used for differential analysis,and the intersection of the differen-tially expressed lncRNA(DElncRNA)of the two datasets was taken.The expression levels of DElncRNA in LUAD tissues and normal control tissues were analyzed using GEPIA2.The expression levels of LINC01088 in platelets of 51 healthy con-trols and 54 LUAD patients were detected by quantitative Real-time PCR(qRT-PCR),and the diagnostic ability of each in-dex was evaluated by ROC curve.Results 8 DElncRNAs and 1 265 DElncRNAs were obtained from GSE183635 and GSE89843 datasets,respectively.The key DElncRNA LINC01088 was selected after intersection.GEPIA2 analysis showed that the expression level of LINC01088 in LUAD tissues was lower than that in normal lung tissues(P<0.05).Platelet LINC01088 was significantly downregulated in patients with LUAD and early-stage LUAD than in healthy controls(P<0.001).The area under the curve(AUC)of platelet LINC01088 in the diagnosis of LUAD was 0.755,the sensitivity was 81.1%,and the specificity was 67.9%.The AUC for early LUAD diagnosis was 0.727,the sensitivity was 80.0%,and the specificity was 67.9%.The AUC of the combined diagnostic model composed of platelet LINC01088 and carcinoembryonic antigen(CEA)for LUAD diagnosis was 0.807,the sensitivity was 89.2%,and the specificity was 71.4%.The AUC for ear-ly LUAD was 0.770,the sensitivity was 86.7%,and the specificity was 71.4%.The combined diagnostic model of platelet LINC01088 and CEA was superior to CEA in the diagnosis of LUAD and early LUAD(Z=-2.288,-2.34,both P<0.05).Conclusion LINC01088 is down-regulated in platelets of LUAD patients.Platelet LINC01088 may be a biomarker for early screening and diagnosis of LUAD.

熊博雯;尹兴;罗怀超;刘鱼

中国医学科学院北京协和医学院输血研究所,四川 成都 610052四川省肿瘤医院 检验科

基础医学

肺腺癌血小板lncRNA早期筛查生物标志物

lung adenocarcinomaplateletslncRNAearly screeningbiomarker

《中国输血杂志》 2024 (003)

283-289 / 7

中国医学科学院医学与健康科技创新工程重大协同创新项目"血液筛查技术体系建立及产品开发"(2021-I2M-1-060)

10.13303/j.cjbt.issn.1004-549x.2024.03.005

评论